0000000000217057

AUTHOR

Lucia Mangone

0000-0002-5089-5178

showing 29 related works from this author

Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study

2016

Liver cancer represents a major clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from liver cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and provide trends in net survival and dynamics of excess mortality rates (EMRs) up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These tren…

MaleCancer ResearchDatabases FactualEpidemiologyTrends in survival0302 clinical medicineBelgiumCancer screeningMedicineCancer registries030212 general & internal medicineRegistriesYoung adultAged 80 and overmedicine.diagnostic_testMortality rateMedical recordLiver NeoplasmsMiddle Aged3. Good healthCancer registries; Europe; Excess mortality rate; Liver cancer; Net survival; Trends in survival;Survival RateEuropeOncologyItaly030220 oncology & carcinogenesisPopulation SurveillanceFemaleFranceLiver cancerLiver cancerSwitzerlandAdultAdolescentSocio-culturale03 medical and health sciencesYoung AdultNet survivalHumansAgedPortugalExcess mortality ratebusiness.industryPublic Health Environmental and Occupational Healthmedicine.diseaseCancer registrySpainLiver functionbusinessLiver function testsDemography
researchProduct

Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: Results from the first Italian population-based cohort

2022

Background: Evidence about late effects in adolescent and young adult (AYA) cancer survivors is scarce. This study assessed the risk of subsequent malignant neoplasms (SMNs) to identify the most common SMNs to be considered in follow-up care. Methods: Population-based cancer registries retrospectively identified first primary tumors (between 1976 and 2013) and SMNs in AYAs (15-39 years old at their cancer diagnosis). AYA cancer survivors were those alive at least 5 years after their first cancer diagnosis. The excess risk of SMNs was measured as standardized incidence ratios (SIRs) and absolute excess risk together with the cumulative incidence of SMNs. Results: The cohort included 67,692 A…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyAdolescentColorectal cancercancer survivorPopulationBreast NeoplasmsSettore MED/42 - Igiene Generale E ApplicataProstate cancerBreast cancerRisk FactorsInternal medicineNeoplasmsfollow-upMedicineHumanscancer survivorsCumulative incidenceadolescentseducationLung cancerRetrospective Studieseducation.field_of_studyBladder cancerbusiness.industryIncidenceCancerregistriesNeoplasms Second Primarymedicine.diseasehumanitiesregistrieOncologyadolescents cancer survivors follow-up registries young adultyoung adultFemalebusiness
researchProduct

Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference

2019

Germ-cell tumours (GCT) of the testis and penile squamous cell carcinoma (PeSCC) are a rare and a very rare uro-genital cancers, respectively. Both tumours are well defined entities in terms of management, where specific recommendations - in the form of continuously up-to-dated guide lines- are provided. Impact of these tumour is relevant. Testicular GCT affects young, healthy men at the beginning of their adult life. PeSCC affects older men, but a proportion of these patients are young and the personal consequences of the disease may be devastating. Deviation from recommended management may be a reason of a significant prognostic worsening, as proper treatment favourably impacts on these t…

OncologyMaleSurvival030232 urology & nephrologyDiseaseCarcinoma; Community network; Europe; Germ cell and embryonal; Neoplasms; Penis neoplasms; Rare diseases; Squamous cell; Survival; Tertiary care centres; Testicular neoplasms; Surgery; Oncology0302 clinical medicineNeoplasmsEpidemiologyTesticular neoplasmReferral and ConsultationPenis neoplasmsCarcinoma ; Community network ; Europe ; Germ cell and embryonal ; Neoplasms ; Penis neoplasms ; Rare diseases ; Squamous cell ; Survival ; Tertiary care centres ; Testicular neoplasmsGeneral MedicineNeoplasms Germ Cell and EmbryonalTertiary care centreRare diseasesSurvival RateEuropeOncology030220 oncology & carcinogenesisLymphatic MetastasisCarcinoma Squamous CellHumanmedicine.medical_specialtyTesticular neoplasmsPenile squamous cell carcinomaGerm cell and embryonalCommunity networkSocio-culturaleCancer Care FacilitiesTertiary care centres03 medical and health sciencesPenis neoplasmRare DiseaseInternal medicinemedicineCarcinomaHumansPenile NeoplasmsNeoplasm StagingPenis Neoplasmsbusiness.industryCancer Care FacilitieSquamous cellCarcinomaLymphatic Metastasimedicine.diseaseTesticular germ cellAdult lifePenile NeoplasmProper treatmentNeoplasmLymph Node ExcisionSurgerybusinessDelivery of Health Care
researchProduct

Epidemiology of rare cancers and inequalities in oncologic outcomes

2019

Rare cancers epidemiology is better known compared to the other rare diseases. Thanks to the long history of the European population-based cancer registries and to the EUROCARE huge database, the burden of rare cancers has been estimated the European (EU28) population. A considerable fraction of all cancers is represented by rare cancers (24%). They are a heterogeneous group of diseases, but they share similar problems: uncertainty of diagnosis, lack of therapies, poor research opportunities, difficulties in clinical trials, lack of expertise and of centres of reference. This paper analyses the major epidemiological indicators of frequency (incidence and prevalence) and outcome (5-year surv…

0301 basic medicineMaleSettore MED/06 - Oncologia Medica0302 clinical medicineNeoplasmsEpidemiologyPrevalenceEurope ; Population-based cancer registry ; Rare cancersChildeducation.field_of_studyRelative survivalIncidence (epidemiology)IncidenceGeneral MedicineMiddle AgedSurvival RateEuropeHealthcare DisparitieOncology030220 oncology & carcinogenesisChild PreschoolFemaleHumanAdultmedicine.medical_specialtyAdolescentEurope; Population-based cancer registry; Rare cancers; Surgery; OncologyPopulationSocio-culturaleEurope Population-based cancer registry Rare cancers03 medical and health sciencesYoung AdultRare DiseasesAge DistributionRare DiseasemedicineHumansRare cancersHealthcare DisparitiesSex DistributioneducationPopulation-based cancer registrySurvival rateAgedbusiness.industryPublic healthInfant NewbornCancerRare cancerInfantmedicine.diseaseClinical trial030104 developmental biologyNeoplasmSurgerybusinessDemography
researchProduct

Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991–2010 (Automated Childhood Cancer Informatio…

2018

List of ACCIS contributors = Monika Hackl, Anna Zborovskaya, Nadya Dimitrova, Zdravka Valerianova, Ladislav Dušek, Margit Mägi, Alain Monnereau, Jacqueline Clavel, Michel Velten, Anne-Valérie Guizard, Véronique Bouvier, Xavier Troussard, Anne-Sophie Woronoff, Emilie Marrer, Brigitte Trétarre, Marc Colonna, Olivier Ganry, Pascale Grosclaude, Berndt Holleczek, Zsuzsanna Jakab, Laufey Tryggvadóttir, Lucia Mangone, Franco Merletti, Stefano Ferretti, Bianca Caruso, Maria Michiara, Rosario Tumino, Fabio Falcini, Roberto Zanetti, Giovanna Tagliabue, Otto Visser, Giske Ursin, Ryszard Mężyk, Kamila Kepska, José Laranja Pontes, Maja Primic Žakelj, Rafael Fernández-Delgado, Marisa L Vicente Raneda, En…

MaleCàncer en els infantsTime FactorsCancer in children0302 clinical medicineRisk FactorsNeoplasms030212 general & internal medicineRegistriesAge of OnsetChildmedia_commoneducation.field_of_studyCancer in adolescenceIncidence (epidemiology)Incidence3. Good healthEuropeOncology030220 oncology & carcinogenesisRegional studiesChild PreschoolFemale2730 OncologyAdolescentPopulationChildhood cancerSocio-culturale610 Medicine & healthRisk AssessmentArticle03 medical and health sciencesYoung AdultAge DistributionSDG 3 - Good Health and Well-beingmedicinemedia_common.cataloged_instanceHumansCàncer en els adolescentsEuropean unioneducationbusiness.industryInfant NewbornCancerInfantHealth Status Disparities10060 Epidemiology Biostatistics and Prevention Institute (EBPI)medicine.diseasePopulation based studyCancer incidencebusinessDemography
researchProduct

Treatment challenges in and outside a network setting: Head and neck cancers.

2019

Head and neck cancer (HNC) is a rare disease that can affect different sites and is characterized by variable incidence and 5-year survival rates across Europe. Multiple factors need to be considered when choosing the most appropriate treatment for HNC patients, such as age, comorbidities, social issues, and especially whether to prefer surgery or radiation-based protocols. Given the complexity of this scenario, the creation of a highly specialized multidisciplinary team is recommended to guarantee the best oncological outcome and prevent or adequately treat any adverse effect. Data from literature suggest that the multidisciplinary team-based approach is beneficial for HNC patients and lea…

0301 basic medicinemedicine.medical_specialtySocio-culturaleSocial issuesMultidisciplinary team03 medical and health sciencesTherapeutic approach0302 clinical medicineRare DiseasesMultidisciplinary approachmedicineHumansAdverse effectIntensive care medicineHead and neck cancerReferral and ConsultationPatient Care TeamEuropean reference networks joint action of rare cancers ; Head and neck cancer ; Multidisciplinary team ; Rare diseasebusiness.industryHead and Neck NeoplasmHead and neck cancerEuropean reference networks joint action of rare cancersGeneral MedicineMultidisciplinary teammedicine.diseaseEurope030104 developmental biologyClinical researchOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisEuropean reference networks joint action of rare cancerSurgerybusinessEuropean reference networks joint action of rare cancers; Head and neck cancer; Multidisciplinary team; Rare disease; Surgery; OncologyRare diseaseDelivery of Health CareRare diseaseHumanEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Epidemiology and biological characteristics of male breast cancer in Italy.

2020

Aim: To evaluate the epidemiology of male breast cancer (MBC) in Italy and to describe incidence and survival data in relation to age, morphology, year of incidence, geographic area, and possible association with other cancers compared with female BC. Methods: Cases were extracted from 40 Italian Cancer Registries. Standardized incidence rates (SIR), age-specific rates, and 5-year survival were calculated. The association with second tumors was also evaluated. All data were compared with data from female BCs. Results: In the 2000–2014 period, 2175 new cases of MBC were registered, with an SIR of 1.7 × 100,000. The incidence showed a slight upward trend and increased with increasing age. The…

0301 basic medicineOncologyMaleReceptor ErbB-2Sex Factormale breast cancerKaplan-Meier Estimate0302 clinical medicineclinical and biological characteristics; male breast cancer; second cancers; stage; survivalMedicinePharmacology (medical)Age FactorBreastRegistriesAged 80 and overclinical and biological characteristicsGeographyIncidence (epidemiology)IncidenceCarcinoma Ductal BreastAge FactorsNeoplasms Second PrimaryGeneral MedicineMiddle Agedsecond cancersSurvival RateOncologyItalyReceptors Estrogen030220 oncology & carcinogenesisMale breast cancerFemaleReceptors ProgesteroneBreast NeoplasmYoung Adult.Adultmedicine.medical_specialtyBreast NeoplasmssurvivalBreast Neoplasms Male03 medical and health sciencesYoung AdultBreast cancerSex FactorsInternal medicineHumansRadiology Nuclear Medicine and imagingRisk factorSurvival rateCancer stagingAgedbusiness.industryCancermedicine.diseasestageCancer registry030104 developmental biologyKi-67 AntigenClinical and biological characteristicbusinessBreast cancer (Tokyo, Japan)
researchProduct

Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours

2019

Pancreatic Neuroendocrine Neoplasms comprise a group of rare tumours with special biology, an often indolent behaviour and particular diagnostic and therapeutic requirements. The specialized biochemical tests and radiological investigations, the complexity of surgical options and the variety of medical treatments that require individual tailoring, mandate a multidisciplinary approach that can be optimally achieved through an organized network. The present study describes currents concepts in the management of these tumours as well as an insight into the challenges of delivering the pathway in and outside a Network.

Liver metastasemedicine.medical_specialtyPathologySocio-culturale03 medical and health sciencesLiver metastasesRare Diseases0302 clinical medicineLiver metastases ; Neuroendocrine tumours ; Pancreas ; Rare cancersNeuroendocrine tumoursMultidisciplinary approachRare DiseaseNeuroendocrine tumourHumansMedicinePancreaRare cancersPrecision MedicineIntensive care medicinePancreasLiver metastases Neuroendocrine tumours Pancreas Rare cancersPatient Care Teambusiness.industryPancreatic NeoplasmRare cancerGeneral MedicinePancreatic NeoplasmsSurvival RateNeuroendocrine TumorsLiver metastases; Neuroendocrine tumours; Pancreas; Rare cancers; Surgery; OncologyOncology030220 oncology & carcinogenesisMandate030211 gastroenterology & hepatologySurgerybusinessNeuroendocrine TumorDelivery of Health CareHuman
researchProduct

Trends in net survival from colon cancer in six European Latin countries: results from the SUDCAN population-based study.

2016

IF 2.415; International audience; Colon cancer represents a major public health issue. The aim of the SUDCAN collaborative study was to compare the net survival from colon cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) and provide trends in net survival and dynamics of the excess mortality rates up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results were reported from 1992 to 2004 in France, Italy, Spain, and Switzerland and from 2000 to 2004 …

MaleCancer ResearchDatabases FactualEpidemiologyColorectal cancer[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineBelgiumEpidemiologyRegistries030212 general & internal medicineYoung adultNet SurvivalAged 80 and overMiddle Aged3. Good healthSurvival RateEuropeTrend analysisGeographyItalyOncologycolon cancerPopulation Surveillance030220 oncology & carcinogenesisColonic NeoplasmsFemaleFrancenet survivalSwitzerlandAdultmedicine.medical_specialtyAdolescent[SDV.CAN]Life Sciences [q-bio]/CancerColorectal-CancerYoung Adult03 medical and health sciencesmedicineHumansMortalitySurvival rateexcess mortality rateMass screeningAgedPortugalPublic healthPublic Health Environmental and Occupational Healthmedicine.diseaseSpaincancer registriestrend analysisFollow-Up StudiesDemography
researchProduct

Neoadjuvant therapy for breast cancer

2019

Objective: To evaluate the frequency of neoadjuvant therapy (NT) in women with stage I–III breast cancer in Italy and whether it is influenced by biological characteristics, screening history, and geographic area. Methods: Data from the High Resolution Study conducted in 7 Italian cancer registries were used; they are a representative sample of incident cancers in the study period (2009–2013). Included were 3546 women aged <85 years (groups <50, 50–69, 70–64, and 75+) with stage I–III breast cancer at diagnosis who underwent surgery. Women were classified as receiving NT if they received chemotherapy, target therapy, and/or hormone therapy before the first surgical treatment. Logistic…

OncologyAdultCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBreast NeoplasmsSettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineBreast cancerBreast cancerInternal medicineCancer screeningmedicineBiomarkers TumorOdds RatioMammographyHumans030212 general & internal medicineneoadjuvant therapyNeoadjuvant therapyTriple-negative breast cancerTumor markerCancer stagingAgedNeoplasm StagingAged 80 and overmedicine.diagnostic_testGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyCancer registryTreatment OutcomeOncology030220 oncology & carcinogenesisFemalemultidisciplinaryMammography
researchProduct

RISK OF HEMOLYMPHOPOIETIC NEOPLASM BEFORE AND AFTER THYROID CANCER. A POPULATION‐BASED STUDY IN ITALY, 1998‐2012

2021

OncologyCancer Researchmedicine.medical_specialtybusiness.industryHematologyGeneral Medicinemedicine.diseasePopulation based studyOncologyInternal medicinemedicineNeoplasmbusinessThyroid cancerHematological Oncology
researchProduct

The impact of overdiagnosis on thyroid cancer epidemic in Italy,1998-2012

2018

Aims: In Italy, incidence rates of thyroid cancer (TC) are among the highest world- wide with substantial intracountry heterogeneity. The aim of the study was to examine time trends of TC incidence in Italy and to estimate the proportion of TC cases potentially attribut- able to overdiagnosis. Methods: Data on TC cases reported to Italian cancer registries during 1998e2012 aged <85 years were included. Age-standardised incidence rates (ASR) were computed by sex, period, and histology. TC overdiagnosis was estimated by sex, period, age, and Italian region. Results: In Italy between 1998e2002 and 2008e2012, TC ASR increased of 74% in women (from 16.2 to 28.2/100,000) and of 90% in men (fro…

MaleCancer ResearchMedical OveruseSettore MED/42 - Igiene Generale E Applicata0302 clinical medicineRegistriesYoung adultOverdiagnosisChildThyroid cancerAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceThyroidTime trendsMiddle Agedmedicine.anatomical_structureOncologyItaly030220 oncology & carcinogenesisChild PreschoolFemalemedicine.symptomAdultIncidence; Italy; Mortality; Overdiagnosis; Thyroid cancer; Time trends; Oncology; Cancer ResearchOverdiagnosisAdolescentPopulationSocio-culturale030209 endocrinology & metabolismAsymptomaticThyroid cancer03 medical and health sciencesYoung AdultmedicineHumansThyroid NeoplasmsMortalityeducationEpidemicsAgedbusiness.industryInfant NewbornCancerInfantmedicine.diseaseOverdiagnosibusinessDemography
researchProduct

Characteristics of the colorectal cancers diagnosed in the early 2000s in Italy. Figures from the IMPATTO study on colorectal cancer screening

2015

The impact of organized screening programmes on colorectal cancer (CRC) can be observed at a population level only several years after the implementation of screening. We compared CRC characteristics by diagnostic modality (screen-detected, non-screen-detected) as an early outcome to monitor screening programme effectiveness. Data on CRCs diagnosed in Italy from 2000 to 2008 were collected by several cancer registries. Linkage with screening datasets made it possible to divide the cases by geographic area, implementation of screening, and modality of diagnosis (screen-detected, non-screen-detected).We compared the main characteristics of the different subgroups of CRCs through multivariate …

Colorectal cancer; Colorectal cancer screening; Italy; Epidemiology; Public Health Environmental and Occupational HealthItalyEpidemiologyPublic Health Environmental and Occupational HealthSettore MED/42 - Igiene Generale E ApplicataColorectal cancerColorectal cancer screening
researchProduct

Trends in net survival from stomach cancer in six European Latin countries: results from the SUDCAN population-based study

2016

IF 2.415; International audience; Gastric cancers are a clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from gastric cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and explore the trends in net survival and in the dynamics of the excess mortality rates (EMRs) up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 200…

MaleCancer ResearchDatabases FactualEpidemiology0302 clinical medicineBelgiumEpidemiologyRegistries030212 general & internal medicineYoung adultStomach cancerNet SurvivalAged 80 and overstomach cancerMiddle Aged3. Good healthSurvival RateEuropeTrend analysisItalyOncologyPopulation Surveillance030220 oncology & carcinogenesisFemaleFrancenet survivalSwitzerlandAdultmedicine.medical_specialtyAdolescent[SDV.CAN]Life Sciences [q-bio]/CancerYoung Adult03 medical and health sciencesStomach NeoplasmsmedicineHumansSurvival rateexcess mortality rateAgedPortugalbusiness.industryCarcinomaPublic Health Environmental and Occupational HealthCancermedicine.diseaseEstrogenPopulation based studyGastric-cancerSpaincancer registriesSurgerytrend analysisbusinessDemography
researchProduct

Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting.

2017

The management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of databases, translational research programs, and clinical trials. Access to innovative strategies represents a major challenge, as there is a lack of funding for clinical research in rare cancers and their rarity precludes the design of robust clinical trials that could lead to specific approval of drugs. In this context, patient-centered initiatives, such as the establishment of dedicated networks, are warranted. International societies, such as IMI…

0301 basic medicineMesotheliomamedicine.medical_specialtyInternational CooperationPleural NeoplasmsMEDLINESocio-culturaleContext (language use)Translational researchDiseaseSocial Networking03 medical and health sciences0302 clinical medicineMultidisciplinary approachMedicineHumansMesotheliomaPleural NeoplasmIntensive care medicinebusiness.industryGeneral MedicineThymus Neoplasmsmedicine.diseaseClinical trialEuropeSurvival Rate030104 developmental biologyClinical researchOncology030220 oncology & carcinogenesisSurgery; OncologySurgerybusinessDelivery of Health Caremesothelioma thymic tumours clinical trialsHumanEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Trends in net survival from 15 cancers in six European Latin countries: the SUDCAN population-based study material

2016

The aim of the SUDCAN collaborative study was to compare the net survival from 15 cancers diagnosed in 2000-2004 in six European Latin countries and provide trends in net survival and dynamics of excess mortality rates up to 5 years after diagnosis from 1992 to 2004 in France, Italy, Spain, and Switzerland, and from 2000 to 2004 in Belgium and Portugal. This paper presents a detailed description of the data analyzed and quality indicators. Incident cases from Belgium, France, Italy, Portugal, Spain, and Switzerland were retrieved from 56 general or specialized population-based cancer registries that participated in the EUROCARE-5 database. Fifteen cancer sites were analyzed. The data were c…

0301 basic medicineCancer Researchmedicine.medical_specialtyDatabases FactualEpidemiology03 medical and health sciences0302 clinical medicineBelgiumNeoplasmsEpidemiologymedicineHumansSurvival rateNet SurvivalSurvival analysisPortugalMortality ratePublic Health Environmental and Occupational HealthSurvival Analysis3. Good healthCancer registryEuropeSurvival RateTrend analysis030104 developmental biologyGeographyItalyOncologySpainPopulation Surveillance030220 oncology & carcinogenesisFranceDeath certificateSwitzerlandFollow-Up StudiesDemographyEuropean Journal of Cancer Prevention
researchProduct

Adolescent and Young Adult Cancer Survivors: Design and Characteristics of the First Nationwide Population-Based Cohort in Italy

2020

Purpose: Adolescent and young adult (AYA, 15-39 years) cancer survivors (alive at least 5 years after cancer diagnosis) are less studied than younger and older cancer survivors and research on their late effects is limited. To facilitate research on long-term outcomes of AYA cancer survivors, we established, in Italy, a population-based AYA cancer survivors' cohort. This article describes the study design and main characteristics of this cohort. Methods: The cohort derives from population-based cancer registries (CRs). Each CR identified AYA cancer patients retrospectively. Treatment for first primary cancer and all health events from diagnosis to death can be traced through linkage with av…

late outcomesAdultMalePediatricsmedicine.medical_specialtyAdolescentlate outcomePopulationSettore MED/42 - Igiene Generale E ApplicataCohort StudiesYoung AdultPopulation based cohortCancer SurvivorsAdministrative databaseHospital dischargeHumansMedicineYoung adulteducationeducation.field_of_studybusiness.industryAbsolute risk reductionCancersurvivorscohortmedicine.diseasehumanitiesItalyOncologypopulation-based dataPediatrics Perinatology and Child HealthCohortFemalebusiness
researchProduct

Trends in Net Survival from Vulvar Squamous Cell Carcinoma in Italy (1990–2015)

2023

(1) Objective: In many Western countries, survival from vulvar squamous cell carcinoma (VSCC) has been stagnating for decades or has increased insufficiently from a clinical perspective. In Italy, previous studies on cancer survival have not taken vulvar cancer into consideration or have pooled patients with vulvar and vaginal cancer. To bridge this knowledge gap, we report the trend in survival from vulvar cancer between 1990 and 2015. (2) Methods: Thirty-eight local cancer registries covering 49% of the national female population contributed the records of 6274 patients. Study endpoints included 1- and 2-year net survival (NS) calculated using the Pohar-Perme estimator and 5-year NS condi…

trendvulvar neoplasmvulvar neoplasmsGeneral MedicineSettore MED/42 - Igiene Generale E Applicatavulvar neoplasms; survival; trendsurvivalJournal of Clinical Medicine
researchProduct

Incidence trends of vulvar squamous cell carcinoma in Italy from 1990 to 2015

2020

The incidence of vulvar squamous cell carcinoma has increased for decades in most Western countries - a trend virtually restricted to women aged50 or 60 years. In southern Europe, conversely, the trends have been insufficiently studied. This article reports a study from Italy.Thirty-eight local cancer registries, currently covering 15,274,070 women, equivalent to 49.2% of the Italian national female population, participated. Invasive cancers registered between 1990 and 2015 with an International Classification of Diseases for Oncology, 3rd revision, topography code C51 and morphology codes compatible with vulvar squamous cell carcinoma (n = 6294) were eligible. Incidence trends were analyse…

0301 basic medicineHistoryVulvar Squamous Cell CarcinomaAge-period-cohort modelling; Incidence; Trend; Vulvar neoplasms; Carcinoma Squamous Cell; Female; History 20th Century; History 21st Century; Humans; Incidence; Italy; Middle Aged; Vulvar NeoplasmsSettore MED/42 - Igiene Generale E ApplicataHistory 21st CenturyNO03 medical and health sciences0302 clinical medicineAge-period-cohort modellingAge-period-cohort modelling; Incidence; Trend; Vulvar neoplasmsTrendHumansMedicineRisk factorVulvar neoplasmVulvar Neoplasmsbusiness.industryIncidenceIncidence (epidemiology)CarcinomaObstetrics and GynecologyHistory 20th CenturyMiddle Aged21st CenturyConfidence intervalCancer registry20th CenturyTrend analysis030104 developmental biologySquamous CellItalyOncology030220 oncology & carcinogenesisVulvar neoplasms incidence trend age-period-cohort modellingCarcinoma Squamous CellFemalebusinessDemographyCohort studyGynecologic Oncology
researchProduct

Management of rectal cancers in relation to treatment guidelines: a population-based study comparing Italian and French patients

2014

Few studies have investigated rectal cancer management at the population level. We compared how rectal cancers diagnosed in Italy (2003-2005) and France (2005) were managed, and evaluated the extent to which management adhered to European guidelines.Samples of 3938 Italian and 2287 French colorectal cancer patients were randomly extracted from 8 and 12 cancer registries respectively. Rectal cancer patients (860 Italian, 559 French) were analysed. Logistic regression models estimated odds ratios (ORs) of being treated with curative intent, receiving sphincter-saving surgery, and receiving preoperative radiotherapy.Similar proportions of Italian and French patients were treated with curative …

Malemedicine.medical_specialtyPreoperative radiotherapyPopulation levelColorectal cancer[SDV]Life Sciences [q-bio]Anal CanalAdenocarcinomaLogistic regressionInternal medicinemedicineHumansComputingMilieux_MISCELLANEOUSAgedAged 80 and overHepatologybusiness.industryRectal NeoplasmsGastroenterologyCancerOdds ratioMiddle Agedmedicine.diseaseNeoadjuvant Therapy3. Good healthSurgeryCancer registryPopulation based studyItalyPractice Guidelines as TopicLymph Node ExcisionFemaleRadiotherapy AdjuvantFranceGuideline AdherencebusinessOrgan Sparing Treatments
researchProduct

Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study

2017

Background: Rare cancers pose challenges for diagnosis, treatments, and clinical decision making. Information about rare cancers is scant. The RARECARE project defined rare cancers as those with an annual incidence of less than six per 100 000 people in European Union (EU). We updated the estimates of the burden of rare cancers in Europe, their time trends in incidence and survival, and provide information about centralisation of treatments in seven European countries. Methods: We analysed data from 94 cancer registries for more than 2 million rare cancer diagnoses, to estimate European incidence and survival in 2000–07 and the corresponding time trends during 1995–2007. Incidence was calcu…

Male0301 basic medicinePathologypopulation-based registriesCancer Care Facilities; Delivery of Health Care; Europe; Female; Hospitalization; Humans; Incidence; Male; Neoplasms; Rare Diseases; Registries; Survival Rate; Oncology0302 clinical medicineNeoplasmsMedicineRegistriesmedia_commonTumors -- Treatment -- Europeeducation.field_of_studyRelative survivalIncidenceIncidence (epidemiology)RARECARE projectEuropeHospitalizationSurvival RateOncology030220 oncology & carcinogenesis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalemedicine.medical_specialtyHealth surveysPopulationSocio-culturaleCancer Care Facilities03 medical and health sciencesRare DiseasesSDG 3 - Good Health and Well-beingHumansmedia_common.cataloged_instanceCancer -- MortalityRisk factorEuropean unioneducationSurvival rateOncology cancer burden incidence rare cancerpopulation-based registriesrare cancers cancer registry RARECAREbusiness.industryRare cancerCancer -- Patients -- Long-term careCancer registry030104 developmental biologycancer burdenbusinessDelivery of Health CareDemographyRare disease
researchProduct

Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998–2012

2021

Abstract Background The number of patients living after a cancer diagnosis is increasing, especially after thyroid cancer (TC). This study aims at evaluating both the risk of a second primary cancer (SPC) in TC patients and the risk of TC as a SPC. Methods We analyzed two population‐based cohorts of individuals with TC or other neoplasms diagnosed between 1998 and 2012, in 28 Italian areas covered by population‐based cancer registries. Standardized incidence ratios (SIRs) of SPC were stratified by sex, age, and time since first cancer. Results A total of 38,535 TC patients and 1,329,624 patients with other primary cancers were included. The overall SIR was 1.16 (95% CI: 1.12–1.21) for SPC i…

MaleOncologyCancer Researchmedicine.medical_specialtypopulation-based cancer registriesPopulationSocio-culturaleSettore MED/42 - Igiene Generale E ApplicataHistory 21st CenturyCohort StudiesRisk FactorsProstateInternal medicinepopulation‐based cancer registriesmedicinethyroid cancerHumanscancer survivorsRadiology Nuclear Medicine and imagingRegistriesThyroid NeoplasmsOverdiagnosiseducationThyroid cancerResearch ArticlesRC254-282cancer survivors; Italy; population-based cancer registries; relative risk; second primary cancer; thyroid cancereducation.field_of_studycancer survivors Italy population-based cancer registries relative risk second primary cancer thyroid cancerbusiness.industryIncidenceIncidence (epidemiology)ThyroidNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerNeoplasms Second PrimaryHistory 20th Centurymedicine.diseaserelative riskmedicine.anatomical_structureOncologyItalyRelative riskFemalesecond primary cancerbusinessCancer PreventionResearch Article
researchProduct

Incidence, survival and prevalence of myeloid malignancies in Europe.

2012

Abstract Background The Surveillance of Rare Cancers in Europe (RARECARE) project aims at increasing knowledge of rare cancers in Europe. This manuscript describes the epidemiology of myeloid malignancies (MMs), taking into account the morphological characterisation of these tumours. Methods We used data gathered by RARECARE on cancer patients diagnosed from 1995 to 2002 and archived in 64 European population-based cancer registries, followed up to 31st December 2003 or later. Results The overall annual crude incidence of MMs was 8.6 per 100,000. Acute myeloid leukaemia (AML) and myeloproliferative neoplasms (MPN) were most common, with incidence rates of 3.7 and 3.1 per 100,000 year respec…

OncologyMyeloidMaleCancer ResearchMyeloidSurvivalChronic myelomonocytic leukaemiaCancer registry Incidence Prevalence Survival Myeloid malignancies Acute myeloid leukaemia Myelodysplastic syndrome Chronic myeloid leukaemia Chronic myelomonocytic leukaemiaImmunophenotypingEpidemiologyPrevalenceChildLeukemiaIncidence (epidemiology)IncidenceMyeloid malignanciesCancer registryMiddle AgedEuropeLeukemia Myeloid AcuteLeukemiamedicine.anatomical_structureOncologyChild PreschoolMyelodysplastic-Myeloproliferative Diseases/epidemiology/mortalityMyelodysplastic Syndromes/epidemiology/mortalityFemaleAdultmedicine.medical_specialtyAdolescentAcute myeloid leukaemiaNOEurope/epidemiologyInternal medicinemedicinecancer Incidence; survival and prevalence; myeloid malignanciesHumansPreschoolChronic myeloid leukaemiaddc:613AgedMyeloproliferative Disorders/epidemiology/mortalityMyeloproliferative Disordersbusiness.industryMyelodysplastic syndromesInfant NewbornCancerInfantcancer Incidencemedicine.diseaseNewbornMyelodysplastic-Myeloproliferative DiseasesCancer registrysurvival and prevalenceMyelodysplastic SyndromesImmunologyAcute/epidemiology/mortalitybusinessMyelodysplastic syndrome
researchProduct

Trends in net survival from rectal cancer in six European Latin countries: results from the SUDCAN population-based study.

2016

Rectal cancer is a common and serious disease. The aim of the SUDCAN collaborative study was to compare the net survival from rectal cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) and provide trends in net survival and dynamics of excess mortality rates up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study-period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain, and Switzerland and from 2000 to 2004 in Belgium and Portugal. These analyses …

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentDatabases FactualEpidemiologyColorectal cancer03 medical and health sciencesYoung Adult0302 clinical medicineBelgiumEpidemiologymedicineHumansRegistriesYoung adultSurvival rateNet SurvivalMass screeningAgedExcess mortalityAged 80 and overPortugalbusiness.industryRectal NeoplasmsPublic Health Environmental and Occupational HealthMiddle Agedmedicine.disease3. Good healthPopulation based studyEuropeSurvival RateOncologyItalySpain030220 oncology & carcinogenesisPopulation Surveillance030211 gastroenterology & hepatologyFemaleFrancebusinessSwitzerlandDemographyEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
researchProduct

Epidemiology and Cancer Prevention

2021

Cancer registries (CR) are essential structures for the recording of neoplasms in order to study their distribution and characteristics among a given population; this, moreover, can help in identifying possible main risk factors linked to some cancer conditions. Prevention nowadays is a fundamental key strategy for the control of neoplasms, and this is the reason why policies and screening programs should be implemented in order to raise awareness and reduce exposure to risk factors.

medicine.medical_specialtyeducation.field_of_studyCancer preventionbusiness.industryEnvironmental healthEpidemiologyPopulationScreening programsMedicineCancerbusinesseducationmedicine.disease
researchProduct

The risk of developing a second, different, cancer among 14 560 survivors of malignant cutaneous melanoma: a study by AIRTUM (the Italian Network of …

2008

The aim of this study was to provide further quantitative data on the risk of second nonmelanoma cancers in patients with cutaneous malignant melanoma (CMM). A cohort of 14 560 population-based patients from the Italian Network of Cancer Registries incident during 1985-2002 were included and followed up for further incident cases and vital status. Standardized incidence ratios (SIR) were used to compare the number of observed second cancers with expected cancers. In a total of 69 581 person-years, 1020 second cancers were registered, of which 804.6 were expected (SIR=1.27; 95% confidence interval 1.19-1.35). The risk was similar for males and females, (SIR=1.27 and 1.26, respectively). The …

OncologyAdultMaleCancer Researchmedicine.medical_specialtySkin NeoplasmsSettore MED/06 - Oncologia MedicaPopulationDermatologyCohort StudiesRisk FactorsInternal medicineEpidemiology of cancerMedicineHumansRegistriesSurvivorseducationMelanomaAgedAged 80 and overeducation.field_of_studybusiness.industryIncidence (epidemiology)CancerNeoplasms Second PrimaryMiddle Agedmedicine.diseasehumanitiesConfidence intervalcutaneous melanomacancerOncologyItalyCohortCutaneous melanomaFemalesecond cancer - survivors - malignant melanomabusinessCohort studyFollow-Up StudiesMelanoma research
researchProduct

Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study

2013

Population-based information on the survival of patients with myeloid malignancies is rare mainly because some entities were not recognized as malignant until the publication of the third revision of the International Classification of Diseases for Oncology and World Health Organization classification in 2000. In this study we report the survival of patients with myeloid malignancies, classified by updated criteria, in Europe. We analyzed 58,800 cases incident between 1995 to 2002 in 48 population-based cancer registries from 20 European countries, classified into HAEMACARE myeloid malignancy groupings. The period approach was used to estimate 5-year relative survival in 2000-2002. The rela…

MaleMyeloidMyeloproliferative disorders -- DiagnosisMyelodysplastic–myeloproliferative diseaseshemic and lymphatic diseasesMyelodysplastic Syndromes/embryology/mortalityRegistriesCàncerCancerAged 80 and overMielomeseducation.field_of_studyRelative survivalMyeloid leukemiaArticlesHematologyMiddle AgedEuropemedicine.anatomical_structureMyelodysplastic-Myeloproliferative Diseases/epidemiology/mortalityAplastic anemia -- TreatmentFemaleAdultmedicine.medical_specialtyAdolescentPopulationMyelodysplastic syndromesmyeloid malignancies; survivalmyeloid malignanciesBone marrow -- TumorssurvivalNOEurope/epidemiologyYoung AdultInternal medicinemedicineHumanseducationSurvival analysisddc:613AgedMedul·la òssia -- TumorsEssential thrombocythemiabusiness.industryMyelodysplastic syndromesmedicine.diseaseThrombocytopeniaMyelodysplastic-Myeloproliferative DiseasesSurvival AnalysisMyelodysplastic SyndromesImmunologyMyélomesbusiness
researchProduct

Italian cancer figures, report 2013: Multiple tumours

2013

This collaborative study, based on data collected by the network of Italian association of cancer registries (AIRTUM), provides updated estimates on the incidence risk of multiple primary cancer (MP). The objective is to highlight and quantify the bidirectional associations between different oncological diseases. The quantification of the excess or decreased risk of further cancers in cancer patients, in comparison with the general population, may contribute to understand the aetiology of cancer and to address clinical follow-up.Data herein presented were provided by AIRTUM population-based cancer registries, which cover nowadays 48% of the Italian population. This monograph utilizes the AI…

AdultMaleData Interpretationcancer incidenceAdolescentEpidemiologySettore MED/42 - Igiene Generale E ApplicataNeoplasms Multiple PrimaryCohort StudiesYoung AdultMultiple PrimaryRisk FactorsNeoplasms80 and overHumansChildPreschoolAgedRetrospective StudiesAged 80 and overIncidenceEnvironmental and Occupational Healthmultiple tumourInfantNeoplasms Second Primaryitalian cancer; multiple tumours; cancer incidenceStatisticalMiddle Ageditalian cancerMultiple primary cancer incidenceAdolescent; Adult; Aged; Aged 80 and over; Child; Child Preschool; Cohort Studies; Data Interpretation Statistical; Female; Humans; Incidence; Infant; Italy; Male; Middle Aged; Neoplasms Multiple Primary; Neoplasms Second Primary; Retrospective Studies; Risk Factors; Young AdultSecond PrimaryItalyChild PreschoolData Interpretation StatisticalEpidemiology; Public Health Environmental and Occupational HealthFemalePublic Health
researchProduct

Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer: Results from the IMPATTO study

2019

To evaluate the impact of faecal immunochemical test (FIT) screening on stage distribution at diagnosis, and to estimate relative incidence rates by stage in screened at first and subsequent rounds vs. unscreened. We included all incident cases occurring in 2000-2008 in 50- to 71-year-olds residing in areas with an FIT-screening programme. Multinomial logistic models were computed to estimate the relative risk ratio (RRR) of stages I and IV, compared to stage II + III, adjusting for age, sex, geographical area, and incidence year. Proportions were then used to estimate incidence rate ratios (IRR) by stage for screened subjects at the first and at subsequent rounds vs. unscreened subjects, a…

MaleCancer Researchmedicine.medical_specialtyColorectal cancerPrevalenceSocio-culturaleColonoscopyColorectal NeoplasmSettore MED/42 - Igiene Generale E Applicatacolorectal cancer screeningScreening programmeFeces03 medical and health sciences0302 clinical medicinecolonoscopyFaecal immunochemical test colonoscopy colorectal cancer screening epidemiology cancer registriesInternal medicineEpidemiologymedicineHumansStage (cooking)Early Detection of CancerAgedNeoplasm StagingProportional Hazards Modelscancer registriemedicine.diagnostic_testFaecal immunochemical testbusiness.industryIncidence (epidemiology)IncidenceMiddle Agedmedicine.diseaseImmunohistochemistryOncologyItalycancer registries030220 oncology & carcinogenesisRelative riskOccult BloodepidemiologyFeceFemaleNeoplasm GradingColorectal NeoplasmsbusinessHuman
researchProduct